HepaHope Senior Management
HepaHope's Senior Management is dedicated to leveraging HepaHope's proprietary technologies to create, develop, produce, and market more effective therapies for liver failure patients, and personalized cancer treatment and better drug screening alternatives.
Officers
- Dr. Park, MD, PhD — President, CEO and CTO
Dr. Park founded HepaHope, Inc. in Silicon Valley, CA in 1999, and HepaHope Korea in Seoul in 2000. He published 40 scientific publications and filed for multiple international patents relating to the science of the bio-artificial liver. - Bhavesh Singh — CFO
Joined HepaHope in January 2009 with over 19 years of experience as a financial advisor to biotech, pharmaceutical, medical device, and healthcare companies.
Board of Directors
- Dr. Park, MD, PhD — Director
- Dr. Gish, MD — Director and Chairman of Science Advisory Board
- Dr. Sussman, MD — Director and Member of the Science Advisory Board
Executive Management
- David Goldberg, PhD — Vice President of Quality Assurance and Quality Control
Joined HepaHope in July 2008 with over 20 years of experience in the pharmaceutical, clinical therapy, blood fractionation and device industries. - Vickie Sheckler — Senior Director of Regulatory Affairs
Joined HepaHope in February 2009 with over 25 years of experience in the biologic and medical device industries, including bio-artificial pancreas development at Novocell, Inc.
- Delai Zhao, MD — Director of Tissue Science
Joined HepaHope in April 2004 having performed hundreds of human liver transplants and done extensive research focused on hepatic arterial blood supply on transplanted livers. - Jaeho Jung, PhD — Director of Research and Development
Joined HepaHope in December 2005 with 14 years post Ph.D. experience in academic and biopharmaceutical industries. - Sungwook Yang — Director of Engineering and Manufacturing
Joined HepaHope in December 2005 with over 15 years of related engineering and manufacturing experience.